COVID19 (disease)
Novavax Approval Process Raises Concerns Among Former Regulators About FDA Integrity
Novavax; FDA approval; COVID-19 vaccine; regulatory process; integrity concerns; delays; political interference
Invivyd Highlights Follow-Up to Pemgarda mAb Could Rival COVID Vaccines
Invivyd; Pemgarda; VYD2311; monoclonal antibody; COVID-19; vaccine alternatives; immune compromise; long-acting protection; phase 1/2 clinical data
BioNTech Acquires CureVac to Advance mRNA Cancer Therapies and End Patent Disputes
BioNTech; CureVac; mRNA; acquisition; COVID-19 vaccine; cancer immunotherapy; merger; patent dispute; biotech merger
FDA Approves Moderna’s Next-Generation Covid Vaccine With Limited Use for Most Healthy People
Moderna; FDA approval; mNexspike; next-generation Covid vaccine; vaccine restrictions; Covid-19; Spikevax; elderly; high-risk medical conditions; Omicron JN.1 variant
Moderna’s Next-Generation COVID Shot Gets FDA Backing With Usage Limitations
Moderna; COVID-19 vaccine; FDA approval; mNEXSPIKE; mRNA-1283; next-generation vaccine; respiratory virus season; age restriction; underlying conditions; vaccine efficacy
Uncertainty Surrounds Moderna’s Next-Generation COVID Shot Amid Policy Changes
Moderna; COVID-19 vaccine; FDA policy; combination flu/COVID-19 shot; vaccine access; mRNA-1083; vaccine recommendations; regulatory setback
RFK Jr. Ends CDC Covid Vaccine Recommendations for Healthy Children and Pregnant Women
RFK Jr.; COVID-19 vaccine; recommendations; children; pregnant women; CDC; HHS Secretary; public health policy
InflaRx Halts Rare Skin Disease Study for Vilobelimab After Futility Signal
InflaRx; vilobelimab; pyoderma gangrenosum; futility; clinical trial; COVID-19; drug development; INF904
FDA Expects ‘Timely Availability’ of Covid Shots as Advisors Update Formula Recommendation
FDA; Covid-19; vaccine; formula update; timely availability; advisory committee; JN.1-lineage; KP.2 strain; 2025-2026
Moderna Shares Fall as Company Withdraws Flu/COVID-19 Combination Vaccine Application
Moderna; mRNA-1083; combination vaccine; flu; COVID-19; FDA; Biologics License Application; vaccine efficacy; clinical trial; share price